Novo Nordisk is testing an IL6 inhibitor, Ziltivekimab, which cut hsCRP levels by ~80-90% in the phase 2 trial: The phase 3 trial is measuring the hard outcomes: cardiovascular death, myocardial infarction, or stroke, in people with established cardiovascular disease, chronic kidney disease, and persistent inflammation
Is B12 supplementation safe for thalassemia patients with iron overload
The effectiveness of glutathione pills can vary depending on factors like the formulation, dosage, and an individuals unique body condition
Metabolomic profiling has demonstrated high accuracies and AUCs in diagnosing ME/CFS
The Phase 2 trial data confirms this: the 1mg dose group achieved only 8.7% weight loss at 48 weeks, indicating that low doses produce modest effects that accumulate slowly
The relationship between stroke recovery and hormonal balance also deserves mention